Corline Biomedical AB omförhandlar avtal med Imperative Care för att bredda kundbearbetningen inom neurovaskulära CHS™-applikationer
November 20, 2024 06:14 ET
|
Corline Biomedical AB
Corline Biomedical AB (”Corline”) meddelar att man tagit initiativ till omförhandling av avtalet med Imperative Care gällande CHS™ för neurovaskulära applikationer. Avtalet är från och med nu...
SurgiBox Announces Strategic Partnership with Accord International to Expand into Japanese Market
November 17, 2024 18:17 ET
|
SurgiBox
TOKYO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- SurgiBox Inc., a leader in portable surgical solutions, is thrilled to announce a strategic partnership with Japanese medical distribution company, Accord...
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
November 14, 2024 13:10 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its...
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
November 14, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate...
electroCore Announces Third Quarter 2024 Financial Results
November 13, 2024 16:01 ET
|
electroCore, Inc.
Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales Company to host a conference call and webcast today, November 13, 2024 at...
Acuitive Technologies Receives FDA 510(k) Clearance for CITREPORE™, A New Synthetic Bioactive Bone Void Filler for Orthopedic Procedures
November 12, 2024 08:00 ET
|
Acuitive Technologies
Acuitive Technologies announced the FDA 510(k) clearance of CITREPORE™, a new synthetic bioactive bone void filler for orthopedic procedures.
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
November 07, 2024 16:05 ET
|
CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
November 04, 2024 06:00 ET
|
R3 Vascular
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...
electroCore to Announce Third Quarter September 30, 2024 Financial Results on Wednesday, November 13, 2024
October 23, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
October 22, 2024 07:00 ET
|
CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected